277 research outputs found

    An annotated list of the Lepidoptera of Honduras

    Get PDF
    A biodiversity inventory of the Lepidoptera of Pico Bonito National Park and vicinity, in the Department of Atlantida of northern Honduras, was initiated in 2009 to obtain baseline data. We present a revised checklist of Honduran butterfly species (updated from the initial 1967 lists), as well as the first comprehensive list of Honduran moths. Our updated list includes 550 species of Papilionoidea, 311 Hesperioidea, and 1,441 moth species

    An annotated list of the Lepidoptera of Honduras

    Get PDF
    A biodiversity inventory of the Lepidoptera of Pico Bonito National Park and vicinity, in the Department of Atlantida of northern Honduras, was initiated in 2009 to obtain baseline data. We present a revised checklist of Honduran butterfly species (updated from the initial 1967 lists), as well as the first comprehensive list of Honduran moths. Our updated list includes 550 species of Papilionoidea, 311 Hesperioidea, and 1,441 moth species

    Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider

    Get PDF
    OBJECTIVE: To update the EULAR 2020 systematic literature review (SLR) on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection. METHODS: As part of a EULAR taskforce, a systematic literature search update was conducted from 11 December 2020 to 14 July 2021. Two reviewers independently identified eligible studies and extracted data on efficacy and safety of immunomodulatory agents used therapeutically in SARS-CoV-2 infection at any stage of disease. The risk of bias (RoB) was assessed with validated tools. RESULTS: Of the 26 959 records, 520 articles were eligible for inclusion. Studies were mainly at high or unclear RoB. New randomised controlled trials (RCTs) on tocilizumab clarified its benefit in patients with severe and critical COVID-19, mainly if associated with glucocorticoids. There are emergent data on the usefulness of baricitinib and tofacitinib in severe COVID-19. Other therapeutic strategies such as the use of convalescent plasma and anti-SARS-CoV-2 monoclonal antibodies showed efficacy in subjects not mounting normal anti-SARS-CoV-2 antibody responses. CONCLUSION: This new SLR confirms that some immunomodulators (tocilizumab and JAK inhibitors) have a role for treating severe and critical COVID-19. Although better evidence is available compared with the previous SLR, the need of RCT with combination therapy (glucocorticoids+anti-cytokines) versus monotherapy with glucocorticoids still remains alongside the need for standardisation of inclusion criteria and outcomes to ultimately improve the care and prognosis of affected people. This SLR informed the 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

    Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

    Get PDF
    BACKGROUND: The SARS-CoV-2 pandemic is a global health problem. Beside the specific pathogenic effect of SARS-CoV-2, incompletely understood deleterious and aberrant host immune responses play critical roles in severe disease. Our objective was to summarise the available information on the pathophysiology of COVID-19. METHODS: Two reviewers independently identified eligible studies according to the following PICO framework: P (population): patients with SARS-CoV-2 infection; I (intervention): any intervention/no intervention; C (comparator): any comparator; O (outcome) any clinical or serological outcome including but not limited to immune cell phenotype and function and serum cytokine concentration. RESULTS: Of the 55 496 records yielded, 84 articles were eligible for inclusion according to question-specific research criteria. Proinflammatory cytokine expression, including interleukin-6 (IL-6), was increased, especially in severe COVID-19, although not as high as other states with severe systemic inflammation. The myeloid and lymphoid compartments were differentially affected by SARS-CoV-2 infection depending on disease phenotype. Failure to maintain high interferon (IFN) levels was characteristic of severe forms of COVID-19 and could be related to loss-of-function mutations in the IFN pathway and/or the presence of anti-IFN antibodies. Antibody response to SARS-CoV-2 infection showed a high variability across individuals and disease spectrum. Multiparametric algorithms showed variable diagnostic performances in predicting survival, hospitalisation, disease progression or severity, and mortality. CONCLUSIONS: SARS-CoV-2 infection affects both humoral and cellular immunity depending on both disease severity and individual parameters. This systematic literature review informed the EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory therapies

    Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider

    Get PDF
    Objective To update the EULAR 2020 systematic literature review (SLR) on efficacy and safety of immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a EULAR taskforce, a systematic literature search update was conducted from 11 December 2020 to 14 July 2021. Two reviewers independently identified eligible studies and extracted data on efficacy and safety of immunomodulatory agents used therapeutically in SARS-CoV-2 infection at any stage of disease. The risk of bias (RoB) was assessed with validated tools. Results Of the 26 959 records, 520 articles were eligible for inclusion. Studies were mainly at high or unclear RoB. New randomised controlled trials (RCTs) on tocilizumab clarified its benefit in patients with severe and critical COVID-19, mainly if associated with glucocorticoids. There are emergent data on the usefulness of baricitinib and tofacitinib in severe COVID-19. Other therapeutic strategies such as the use of convalescent plasma and anti-SARS-CoV-2 monoclonal antibodies showed efficacy in subjects not mounting normal anti-SARS-CoV-2 antibody responses. Conclusion This new SLR confirms that some immunomodulators (tocilizumab and JAK inhibitors) have a role for treating severe and critical COVID-19. Although better evidence is available compared with the previous SLR, the need of RCT with combination therapy (glucocorticoids+anti-cytokines) versus monotherapy with glucocorticoids still remains alongside the need for standardisation of inclusion criteria and outcomes to ultimately improve the care and prognosis of affected people. This SLR informed the 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

    Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

    Get PDF
    Background The SARS-CoV-2 pandemic is a global health problem. Beside the specific pathogenic effect of SARS-CoV-2, incompletely understood deleterious and aberrant host immune responses play critical roles in severe disease. Our objective was to summarise the available information on the pathophysiology of COVID-19. Methods Two reviewers independently identified eligible studies according to the following PICO framework: P (population): patients with SARS-CoV-2 infection; I (intervention): any intervention/no intervention; C (comparator): any comparator; O (outcome) any clinical or serological outcome including but not limited to immune cell phenotype and function and serum cytokine concentration. Results Of the 55 496 records yielded, 84 articles were eligible for inclusion according to question-specific research criteria. Proinflammatory cytokine expression, including interleukin-6 (IL-6), was increased, especially in severe COVID-19, although not as high as other states with severe systemic inflammation. The myeloid and lymphoid compartments were differentially affected by SARS-CoV-2 infection depending on disease phenotype. Failure to maintain high interferon (IFN) levels was characteristic of severe forms of COVID-19 and could be related to loss-of-function mutations in the IFN pathway and/or the presence of anti-IFN antibodies. Antibody response to SARS-CoV-2 infection showed a high variability across individuals and disease spectrum. Multiparametric algorithms showed variable diagnostic performances in predicting survival, hospitalisation, disease progression or severity, and mortality. Conclusions SARS-CoV-2 infection affects both humoral and cellular immunity depending on both disease severity and individual parameters. This systematic literature review informed the EULAR ‘points to consider’ on COVID-19 pathophysiology and immunomodulatory therapies

    Integrated management of a Swiss cropland is not sufficient to preserve its soil carbon pool in the long term

    Get PDF
    Croplands are involved in the exchange of carbon dioxide (CO2) between the atmosphere and the biosphere. Furthermore, soil carbon (C) stocks play an important role in soil fertility. It is thus of great interest to know whether intensively managed croplands act as a net source or sink of atmospheric CO2 and if soil C stocks are preserved over long timescales. The FluxNet site CH-Oe2 in Oensingen, Switzerland, has been operational since the end of 2003. This cropland is managed under the Swiss framework of the Proof of Ecological Performance (PEP, a variant of integrated management) with a crop rotation centred on winter wheat, which also includes winter barley, winter rapeseed, peas, potato and intermediate cover crops. In addition to eddy covariance measurements, meteorological and soil measurements were available along with information on C imports and exports from organic fertilisation, sowing and harvesting. This study investigates cropland C budgets over 13 years and assesses whether the PEP regulations resulted in a balanced C budget. The strongest CO2 uptake was observed during cereal seasons. C export through harvest, however, offset the strong uptake of the cereal crops. The largest net CO2 emissions to the atmosphere were observed during pea and cover crop seasons. Net biome production, representing the overall C budget (assuming carbon leaching to groundwater to be negligible), typically ranged between close to C neutral to C losses of up to 407&thinsp;g&thinsp;C&thinsp;m−2 per season, with peas being the largest source. Overall, the field lost 1674&thinsp;g&thinsp;C&thinsp;m−2 over 13 years (129&thinsp;g&thinsp;C&thinsp;m−2&thinsp;yr−1), which was confirmed by soil C stock measurements at the beginning and the end of the study period. Although managing the field under the regulations of PEP did not result in an overall C sink, model simulations showed that the use of cover crops reduced the C losses compared to leaving the field bare. The use of solid manure improved the C budget by importing substantial amounts of C into the soil, while liquid manure had only a small effect. We thus conclude that additional efforts are needed to bring Swiss management practices closer to the goal of preserving soil C in the long term.</p

    Sphagnum farming from species selection to the production of growing media : a review

    Get PDF
    Sphagnum farming - the production of Sphagnum biomass on rewetted bogs - helps towards achieving global climate goals by halting greenhouse gas emissions from drained peat and by replacing peat with a renewable biomass alternative. Large-scale implementation of Sphagnum farming requires a wide range of know-how, from initial species selection up to the final production and use of Sphagnum biomass based growing media in horticulture. This article provides an overview of relevant knowledge accumulated over the last 15 years and identifies open questions.Peer reviewe

    Better together: data harmonization and cross-study analysis of abdominal MRI data from UK Biobank and the German National Cohort

    Get PDF
    OBJECTIVES: The UK Biobank (UKBB) and German National Cohort (NAKO) are among the largest cohort studies, capturing a wide range of health-related data from the general population, including comprehensive magnetic resonance imaging (MRI) examinations. The purpose of this study was to demonstrate how MRI data from these large-scale studies can be jointly analyzed and to derive comprehensive quantitative image-based phenotypes across the general adult population. MATERIALS AND METHODS: Image-derived features of abdominal organs (volumes of liver, spleen, kidneys, and pancreas; volumes of kidney hilum adipose tissue; and fat fractions of liver and pancreas) were extracted from T1-weighted Dixon MRI data of 17,996 participants of UKBB and NAKO based on quality-controlled deep learning generated organ segmentations. To enable valid cross-study analysis, we first analyzed the data generating process using methods of causal discovery. We subsequently harmonized data from UKBB and NAKO using the ComBat approach for batch effect correction. We finally performed quantile regression on harmonized data across studies providing quantitative models for the variation of image-derived features stratified for sex and dependent on age, height, and weight. RESULTS: Data from 8791 UKBB participants (49.9% female; age, 63 ± 7.5 years) and 9205 NAKO participants (49.1% female, age: 51.8 ± 11.4 years) were analyzed. Analysis of the data generating process revealed direct effects of age, sex, height, weight, and the data source (UKBB vs NAKO) on image-derived features. Correction of data source-related effects resulted in markedly improved alignment of image-derived features between UKBB and NAKO. Cross-study analysis on harmonized data revealed comprehensive quantitative models for the phenotypic variation of abdominal organs across the general adult population. CONCLUSIONS: Cross-study analysis of MRI data from UKBB and NAKO as proposed in this work can be helpful for future joint data analyses across cohorts linking genetic, environmental, and behavioral risk factors to MRI-derived phenotypes and provide reference values for clinical diagnostics
    • …
    corecore